9310 Athena Circles
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com and follow us on Twitter @IncResilience
Where to Find Us: Biotech Beach | Pharm Country | Genetown | BioNC
11 articles with Resilience
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
Resilience Becomes Biomanufacturing Resource Partner for California Institute for Regenerative Medicine
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, was named by the California Institute for Regenerative Medicine (CIRM) as one of the initial Industry Resource Partners within its Industry Alliance Program (IAP).
Resilience Announces Collaboration to Manufacture and Deliver Biotherapeutics for Rare and Complex Conditions
National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing
Up-round financing follows a previously unannounced $600 million Series C Financing completed in August 2021.
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit
National Resilience, Inc. today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
National Resilience, Inc. today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxin.
Resilience Acquires SwiftScale Biologics, a Leader in Cell-Free Protein Synthesis Technology
National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing cell-free protein synthesis (CFPS) technology.
Resilience Joins Forces with Childen’s Hospital of Philadelpia to Develop Next-Generation Biomanufacturing Technologies, Create Impactful Therapies
National Resilience, Inc. announced a strategic collaboration with Children’s Hospital of Philadelphia ( CHOP ) to implement next-generation biomanufacturing technologies and capabilities aimed at accelerating the creation of impactful therapies and technologies for the benefit of patients.
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness
National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced that the Government of Canada will invest CAD 199.2 million ($163.8 million), through the Strategic Innovation Fund , in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.